Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer

被引:26
作者
Gandaglia, Giorgio [1 ,2 ]
Sun, Maxine [1 ]
Huc, Jim C. [3 ]
Novara, Giacomo [4 ]
Choueiri, Toni K. [5 ]
Nguyen, Paul L. [6 ]
Schiffmann, Jonas [1 ]
Graefen, Markus [7 ]
Shariat, Shahrokh F. [8 ]
Abdollah, Firas [2 ]
Briganti, Alberto [2 ]
Montorsi, Francesco [2 ]
Quoc-Dien Trinh [9 ]
Karakiewicz, Pierre I. [1 ]
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 3J4, Canada
[2] Univ Vita Salute San Raffaele, Urol Res Inst, Milan, Italy
[3] Calif State Univ Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90032 USA
[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Urol Clin, Padua, Italy
[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol,Div Urol,Med Sch, Boston, MA 02115 USA
[7] Univ Hosp Hamburg Eppendorf, Martini Klin, Hamburg, Germany
[8] Med Univ Vienna, Dept Urol, Vienna, Austria
[9] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Surg,Div Urol,Med Sch, Boston, MA 02115 USA
关键词
Androgen deprivation therapy; Prostate cancer; Side effects; Renal failure; Competing risks; Acute kidney injury; ANDROGEN-DEPRIVATION THERAPY; ACUTE-RENAL-FAILURE; CARDIOVASCULAR-DISEASE; MEN; RISK; MORTALITY; CARCINOMA; GNRH;
D O I
10.1016/j.eururo.2014.01.026
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Androgen deprivation therapy (ADT) might increase the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). Objective: To examine the impact of ADT on AKI in a large contemporary cohort of patients with nonmetastatic PCa representing the US population. Design, setting, and participants: Overall, 69 292 patients diagnosed with nonmetastatic PCa between 1995 and 2009 were abstracted from the Surveillance Epidemiology and End Results-Medicare database. Outcomes measurements and statistical analyses: Patient in both treatment arms (ADT vs no ADT) were matched using propensity-score methodology. Ten-year AKI rates were estimated. Competing-risks regression analyses tested the association between ADT and AKI, after adjusting for the risk of death during follow-up. Results and limitations: Overall, the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p < 0.001). When patients were stratified according to the type of ADT, the 10-yr AKI rates were 31.1% versus 26.0% for men treated with gonadotropin-releasing hormone (GnRH) agonists and bilateral orchiectomy, respectively (p < 0.001). In multivariable analyses, the administration of GnRH agonists (hazard ratio [HR]: 1.24; 95% confidence interval [CI], 1.18-1.31; p < 0.001), but not bilateral orchiectomy (HR: 1.11; 95% CI, 0.96-1.29; p = 0.1), was associated with the risk of experiencing AKI. Our study is limited by its retrospective design. Conclusions: ADT is associated with an increased risk of AKI in patients with nonmetastatic PCa. In particular, the administration of GnRH agonists, but not surgical castration, may substantially increase the risk of experiencing AKI. These observations should help provide physicians with better patient selection to reduce the risk of AKI. Patient summary: The administration of gonadotropin-releasing hormone agonists, but not bilateral orchiectomy, increases the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). These observations should help provide physicians with better patient selection to reduce the risk of AKI in PCa patients. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1125 / 1132
页数:8
相关论文
共 50 条
  • [31] Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
    Beckmann, Kerri
    Garmo, Hans
    Adolfsson, Jan
    Bosco, Cecilia
    Johansson, Eva
    Robinson, David
    Holmberg, Lars
    Stattin, Par
    Van Hemelrijck, Mieke
    [J]. EUROPEAN UROLOGY, 2019, 75 (04) : 676 - 683
  • [32] Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
    Fontana, Fabrizio
    Marzagalli, Monica
    Montagnani Marelli, Marina
    Raimondi, Michela
    Moretti, Roberta M.
    Limonta, Patrizia
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (24) : 1 - 23
  • [33] Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study
    Lebret, Thierry
    Culine, Stephane
    Davin, Jean-Louis
    Hennequin, Christophe
    Mignard, Jean-Pierre
    Moreau, Jean-Luc
    Rossi, Dominique
    Zerbib, Marc
    Mahmoudi, Abdel
    Latorzeff, Igor
    [J]. AGING MALE, 2014, 17 (02) : 87 - 93
  • [34] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Viroj Wiwanitkit
    [J]. Sexuality and Disability, 2006, 24 : 175 - 178
  • [35] Electrocardiogram Changes Following the Treatment with Gonadotropin-Releasing Hormone Agonists in Patients with Precocious Puberty
    Shiva, Siamak
    Samadi, Mahmoud
    Bagherzadeh, Ali
    Sadat-Ebrahimi, Seyyed-Reza
    [J]. INTERNATIONAL JOURNAL OF PEDIATRICS-MASHHAD, 2021, 9 (11): : 14867 - 14876
  • [36] Gonadotropin-releasing hormone receptors in prostate tissue
    Bono, AV
    Salvadore, M
    Celato, N
    [J]. ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 2002, 24 (04): : 221 - 227
  • [37] Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy
    Chang, Wei-Ting
    Hong, Chon-Seng
    Hsieh, Kun-Lin
    Chen, Yi-Chen
    Ho, Chung-Han
    Shih, Jhih-Yuan
    Kan, Wei-Chih
    Chen, Zhih-Cherng
    Lin, You-Cheng
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists
    Matveev, V. B.
    Alekseev, B. Ya
    Kamolov, B. Sh
    Markova, A. S.
    [J]. ONKOUROLOGIYA, 2021, 17 (02): : 83 - 92
  • [39] Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
    Zhang, Xianlu
    Zhang, Gejun
    Wang, Jianfeng
    Wang, Yanli
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [40] Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
    Anderson, John
    [J]. FUTURE ONCOLOGY, 2009, 5 (04) : 433 - 443